Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-12-09Clinical Trial Update: PEG-Asparaginase Associated Pancreatitis, Hepatotoxicity and Hyperlipidemia in Children With ALL
Clinical trial update notes pancreatitis, hepatotoxicity and hyperlipidemia associated with PEG-asparaginase in children with acute lymphobl…
-
CLINICAL_TRIALS trial_result · 2016-12-07Clinical Trial Update: Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) [Phase 1]
Phase 1 clinical trial update evaluating peg-aspargase with combination chemotherapy in younger patients with newly diagnosed high-risk acut…
-
CLINICAL_TRIALS trial_result · 2016-12-06Clinical Trial Update: PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma [Phase 1, Phase 2]
Clinical trial update describing the evaluation of PCAR-119 Bridge Immunotherapy as a pre-transplant treatment for CD19-positive leukemias a…
-
FDA approval · 2016-11-28FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2016-11-23Clinical Trial Update: Rapamycin in Relapsed Acute Lymphoblastic Leukemia [Phase 1]
Phase 1 trial of Rapamycin for relapsed acute lymphoblastic leukemia has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-11-03Clinical Trial Update: The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents [Phase 4]
Phase 4 pharmacokinetic study of PEG-rhG-CSF in children and adolescents with acute lymphoblastic leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2016-10-25Clinical Trial Update: CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]
Clinical trial update on CD19-targeted CAR-T cell therapy being tested in relapsed/refractory leukemias and lymphomas (Phase 1 and Phase 2).
-
CLINICAL_TRIALS trial_result · 2016-10-14Clinical Trial Update: Statin Therapy in Young Adult Survivors of Childhood Cancer [Phase 2]
Phase 2 clinical trial update evaluating statin therapy for cardiovascular risk reduction in young adult survivors of childhood cancer; the …
-
CLINICAL_TRIALS trial_result · 2016-10-14Clinical Trial Update: Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia [Phase 1]
Phase 1 clinical trial evaluating CART-19 cell therapy for B cell acute lymphoblastic leukemia, reporting efficacy signals.
-
CLINICAL_TRIALS research · 2016-10-12Clinical Trial Update: Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study)
A completed status update for the California Childhood Leukemia Study, a molecular epidemiology study investigating childhood leukemia. The …
-
FDA label_change · 2016-10-07FDA Approved: ONCASPAR — Supplemental Application (Servier Pharmaceuticals LLC)
FDA approved a Supplemental Application for ONCASPAR (pegaspargase) from Servier Pharmaceuticals LLC, updating the product labeling.
-
CLINICAL_TRIALS trial_result · 2016-10-07Clinical Trial Update: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating dasatinib in combination with chemotherapy for newly diagnosed acute lymphoblastic leukemia, including B…
-
CLINICAL_TRIALS research · 2016-09-30Clinical Trial Update: Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study [Phase 4]
This entry reports a Phase 4 clinical trial update for a Malaysia-Singapore Acute Lymphoblastic Leukemia study; current status is not specif…
-
FDA approval · 2016-09-27FDA Approved: DASATINIB — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for dasatinib submitted by Prasco Laboratories.
-
CLINICAL_TRIALS trial_result · 2016-09-20Clinical Trial Update: Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia [EARLY_Phase 1]
An early-phase trial investigates using granulocyte colony-stimulating factor (G-CSF) to disrupt the bone marrow microenvironment in acute l…
-
CLINICAL_TRIALS trial_result · 2016-09-12Clinical Trial Update: Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit [Phase 1]
This update reports the completion of a Phase 1 trial evaluating a single treatment with FT1050, an ex-vivo modulated umbilical cord blood u…
-
FDA approval · 2016-09-07FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) from Takeda Pharmaceuticals America, resulting in changes to t…
-
CLINICAL_TRIALS trial_result · 2016-09-05Clinical Trial Update: Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia [Phase 2]
A phase 2 trial evaluating dasatinib with low-intensity chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia has c…
-
FDA approval · 2016-08-25FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for GLEEVEC (imatinib mesylate) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS research · 2016-08-22Clinical Trial Update: Effect of Enteral Docosahexaenoic Acid Administration in Children With Acute Lymphoblastic Leukemia [Phase 2]
This entry reports the completion of a Phase 2 trial evaluating enteral docosahexaenoic acid in children with acute lymphoblastic leukemia (…
-
CLINICAL_TRIALS trial_result · 2016-08-19Clinical Trial Update: Umbilical Cord Blood Transplant for Hematological Malignancies [Phase 1]
Phase 1 clinical trial evaluating umbilical cord blood transplantation for hematologic malignancies has completed enrollment and reporting.
-
CLINICAL_TRIALS trial_result · 2016-08-18Clinical Trial Update: Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation [Phase 2]
Phase 2 trial update evaluating immunotherapy for relapse after allogeneic transplantation in acute myeloid leukemia, acute lymphoblastic le…
-
FDA approval · 2016-08-17FDA Approved: IMATINIB MESYLATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application for imatinib mesylate, a generic version of the cancer drug, to update its approval status.
-
CLINICAL_TRIALS trial_result · 2016-08-12Clinical Trial Update: An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia [Phase 1]
This is a Phase 1 ascending-dose study of KW-2449 in patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syn…
-
CLINICAL_TRIALS trial_result · 2016-08-04Clinical Trial Update: Sitagliptin Umbilical Cord Blood Transplant Study [Phase 2]
Phase 2 clinical trial update on sitagliptin in the setting of umbilical cord blood transplantation, with results posted in 2016 for several…